Clinical Trials

Now Enrolling People with Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) For A Research Study Phase 2 ALXN1210-NEPH-202 Study (clinicaltrials.gov NCT04564339) Purpose of Study The purpose of this clinical …

The RUBY-3 Study: This clinical study is evaluating povetacicept, a new investigational drug, in people with IgA nephropathy (IgAN) and other autoimmune diseases of the kidney. Povetacicept is designed to reduce the inflammation and harmful antibodies that damage the kidneys, thereby reducing or possibly reversing kidney damage.

Have you been diagnosed with IgA nephropathy? The ASSIST study is a phase 2, randomized, placebo-controlled, cross-over study of atrasentan* in adults with IgA nephropathy (IgAN). The ASSIST study is …

APPLAUSE-IgAN is a Phase 3 global clinical trial that will look at the effects of an investigational drug, iptacopan (LNP023), in people with IgAN. The trial will study the effects of iptacopan (LNP023) on reducing inflammation and kidney damage in people with IgAN.

Are you living with IgA nephropathy? The BEYOND study is a phase 3, randomized, double-blind, placebo-controlled study of zigakibart(BION-1301) in adults with IgA nephropathy (IgAN). The BEYOND study is a …

Travere Therapeutics is evaluating a study medication called sparsentan to determine if it will be a safe and effective treatment that helps slow the decline of kidney function in children living with rare kidney diseases.

The RestoreD Study is a clinical research study evaluating an oral investigational medication, ALXN2050, that may help participants manage their Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) symptoms.

VISIONARY: A Phase 3 clinical trial of sibeprenlimab for adults with IgA Nephropathy. Targeting a brighter future for IgAN patients.

ORIGIN 3 is a Phase 3 clinical trial researching an investigational medication called atacicept in adults with IgAN. The trial will measure the effectiveness of atacicept at improving kidney function by preventing damage caused by the buildup of IgA in the kidneys.